Compare BioNTech SE - ADR (BNTX) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Toyota Motor Corp — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Toyota Motor Corp trades at $189.35 (market cap $221.79B). The key difference: Toyota Motor Corp is far larger — about 9.5× BioNTech SE - ADR's market cap, and Toyota Motor Corp pays a 3.3% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TM | |
|---|---|---|
Market Cap | $23.31B | $221.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $248.29 |
52-Week Low | $83.89 | $166.50 |
Enterprise Value | $6.60B | $414.06B |
Dividend Yield | — | 3.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Toyota Motor trades at $188.22, down 0.3% over 24 hours, with a bullish technical signal and strong fundamentals including a low P/E of 8.53 and consistent earnings beats. Recent news highlights a major vehicle recall and mixed quarterly results, with revenue growth offset by cost pressures.
The outlook is cautiously optimistic given attractive valuation and hybrid vehicle strength, but risks include recall costs, China sales weakness, and macroeconomic headwinds. Analyst consensus leans Hold, reflecting balanced growth prospects against near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
